Journal of Clinical Oncology, Vol 15, 3464-3470, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

JD Hainsworth, JR Gray, SL Stroup, LA Kalman, JE Patten, LG Hopkins, M Thomas and FA Greco
Sarah Cannon Cancer Center and The Minnie Pearl Cancer Research Network, Nashville, TN 37203, USA.

PURPOSE: In two sequential phase II studies, we evaluate the feasibility and efficacy of adding paclitaxel to a standard platinum/etoposide regimen in the first-line treatment of small-cell lung cancer. PATIENTS AND METHODS: One hundred seventeen patients with small-cell lung cancer were treated between June 1993 and July 1996. The first 38 patients received a lower-dose regimen: paclitaxel 135 mg/m2 by 1-hour infusion, carboplatin at an area under the concentration-time curve (AUC) of 5.0, and etoposide 50 mg alternating with 100 mg orally on days 1 to 10. When only mild myelosuppression was observed, doses of paclitaxel and carboplatin were increased in the subsequent 79 patients (paclitaxel 200 mg/m2 by 1-hour infusion and carboplatin at an AUC of 6.0). All patients received four courses of treatment, administered at 21-day intervals. Patients with limited- stage small-cell lung cancer also received thoracic radiation therapy (1.8 Gy/d; total dose, 45 Gy) administered concurrently with courses 3 and 4 of chemotherapy. RESULTS: Seventy-two of 79 patients (91%) who receive the higher-dose regimen had major responses. Thirty-two of 38 (84%) with extensive-stage disease responded (21% complete response rate); median survival was 10 months for this group. With limited-stage disease, the overall response rate was 98%, with 71% complete responses; the median survival time has not been reached at 16 months. Median survival in extensive-stage patients was longer in patients who received the higher-dose regimen (10 months) than in the previous group treated with lower doses (7 months; P = .008). The higher-dose regimen was well tolerated, with myelosuppression being the major toxicity. Compared with the lower-dose regimen, grade 3/4 neutropenia increased from 8% to 38% of courses, but the incidence of hospitalization for neutropenia and fever did not increase. Other nonhematologic toxicities were uncommon, and did not increase substantially with the higher-dose regimen. CONCLUSION: Paclitaxel can be added at full dose (200 mg/m2) to a carboplatin/etoposide combination while maintaining a tolerable toxicity profile. Median survival times in both extensive- and limited- stage patients compare favorably with other reported regimens. This regimen merits further investigation, and a randomized trial to compare this regimen with a standard carboplatin/etoposide combination is underway.

This article has been cited by other articles:

				J. D. Hainsworth, D. R. Spigel, S. Litchy, and F. A. Greco Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study J. Clin. Oncol., August 1, 2006; 24(22): 3548 - 3554. [Abstract] [Full Text] [PDF]

				H. B. Niell, J. E. Herndon II, A. A. Miller, D. M. Watson, A. B. Sandler, K. Kelly, R. S. Marks, M. C. Perry, R. H. Ansari, G. Otterson, et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 J. Clin. Oncol., June 1, 2005; 23(16): 3752 - 3759. [Abstract] [Full Text] [PDF]

				A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]

				E. Felip, R. Rosell, M. Domine, L. Santome, P. Garrido, A. Font, A. Carrato, J. Terrasa, C. Vadell, J. M. Mane, et al. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study Ann. Onc., October 1, 2003; 14(10): 1549 - 1554. [Abstract] [Full Text] [PDF]

				M. Reck, J. von Pawel, H.-N. Macha, E. Kaukel, K.-M. Deppermann, R. Bonnet, K. Ulm, S. Hessler, and U. Gatzemeier Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer J Natl Cancer Inst, August 6, 2003; 95(15): 1118 - 1127. [Abstract] [Full Text] [PDF]

				C. Lu, R. Komaki, J. S. Lee, D. M. Shin, J. L. Palmer, B. J. Coldman, K. M. Pisters, J. M. Kurie, F. V. Fossella, and B. S. Glisson A Phase I Study of Topotecan/Paclitaxel Alternating with Etoposide/Cisplatin and Thoracic Irradiation in Patients with Limited Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2085 - 2091. [Abstract] [Full Text] [PDF]

				C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer Ann. Onc., April 1, 2002; 13(4): 539 - 545. [Abstract] [Full Text] [PDF]

				R. M. Bremnes, S. Sundstrom, J. Vilsvik, and U. Aasebo Multicenter Phase II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3532 - 3538. [Abstract] [Full Text] [PDF]

				P. Thomas, O. Castelnau, D. Paillotin, H. Lena, G. Robinet, J. F. Muir, P. Delaval, S. Gouva, P. Balmes, F. Blanchon, et al. Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Francais de Pneumo-Cancerologie Study J. Clin. Oncol., March 1, 2001; 19(5): 1320 - 1325. [Abstract] [Full Text] [PDF]

				M. H. Cohen Thalidomide in the treatment of high-grade gliomas. J. Clin. Oncol., October 1, 2000; 18(19): 3453 - 3453. [Full Text] [PDF]

				K. Kelly New Chemotherapy Agents for Small Cell Lung Cancer Chest, April 1, 2000; 117(4_suppl_1): 156S - 162S. [Abstract] [Full Text] [PDF]

				K. Kelly, Z. Pan, M. E. Wood, J. Murphy, and P. A. Bunn Jr. A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., November 1, 1999; 5(11): 3419 - 3424. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				B. S. Glisson, J. M. Kurie, R. Perez-Soler, N. J. Fox, W. K. Murphy, F. V. Fossella, J. S. Lee, M. B. Ross, D. A. Nyberg, K. M.W. Pisters, et al. Cisplatin, Etoposide, and Paclitaxel in the Treatment of Patients With Extensive Small-Cell Lung Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2309 - 2309. [Abstract] [Full Text] [PDF]

				H. J.M. Groen, E. Fokkema, B. Biesma, B. Kwa, J. W.G. van Putten, P. E. Postmus, and E. F. Smit Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule J. Clin. Oncol., March 1, 1999; 17(3): 927 - 927. [Abstract] [Full Text] [PDF]

				J. R. Brahmer and D. S. Ettinger Carboplatin in the Treatment of Small Cell Lung Cancer Oncologist, June 1, 1998; 3(3): 143 - 154. [Abstract] [Full Text]